Kelledy Manson - Concepedia

Concepedia

Author

Kelledy Manson

Harvard University

Also Known As

K H Manson, K Manson, K. MANSON, K. Manson, KELLEDY MANSON, Kelledy H Manson, Kelledy H. Manson, Kelledy Manson

57

Publications

5.7K

Citations

36

H-Index

58

Concepts

All Affiliations

Harvard University Duke Medical Center Dana-Farber Cancer Institute Duke University Hospital University of Pennsylvania

KM

About

Kelledy Manson is an author at Harvard University specializing in medicine, immunology, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	28	3.1K
2	Allergy	3	3	248
3	Health Sciences	1	1	46
4	Natural Sciences	1	1	17
5	Public Health	1	1	17

Kelledy Manson

×

49

Publications

5.7K

Citations

36

H-Index

	Year	Citations
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer Philip W. Kantoff, Thomas Schuetz, Brent A. Blumenstein, Journal of Clinical Oncology	2010	969
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer Patrick A. Ott, Siwen Hu‐Lieskovan, Bartosz Chmielowski, Cell UrologyMedicinePhase Ib TrialImmune Checkpoint InhibitorCancer Treatment	2020	699
Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations Harriet L. Robinson, David C. Montefiori, R. Paul Johnson, Nature Medicine VaccinationHuman RetrovirusImmunologyAntiviral ResponseVirology	1999	380
Vaccine protection by a triple deletion mutant of simian immunodeficiency virus Michael S. Wyand, Kelledy Manson, M Garcia-Moll, Journal of Virology ImmunologyPathologySimian Immunodeficiency VirusTwelve Rhesus MonkeysVaccine Target	1996	320
Simian immunodeficiency virus DNA vaccine trial in macaques Shan Lu, James Arthos, David C. Montefiori, Journal of Virology VaccinationVaccine DevelopmentDna PlasmidsRhesus MacaquesVaccine Target	1996	239
Protection by Live, Attenuated Simian Immunodeficiency Virus against Heterologous Challenge Michael S. Wyand, Kelledy Manson, David C. Montefiori, Journal of Virology	1999	223
Highly Attenuated Vaccine Strains of Simian Immunodeficiency Virus Protect against Vaginal Challenge: Inverse Relationship of Degree of Protection with Level of Attenuation R. Paul Johnson, Jeffrey D. Lifson, Susan Czajak, Journal of Virology	1999	218
Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer Mark M. Awad, Ramaswamy Govindan, Kristen N. Balogh, Cancer Cell MedicineImmunologyTherapeutic VaccineBronchial NeoplasmImmune Checkpoint Inhibitor	2022	200
A Phase I Trial of Pox PSA vaccines (PROSTVAC®-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer R. Dipaola, Mark Plante, Howard L. Kaufman, Journal of Translational Medicine	2006	192
Simian Immunodeficiency Virus (SIV)<i>gag</i>DNA-Vaccinated Rhesus Monkeys Develop Secondary Cytotoxic T-Lymphocyte Responses and Control Viral Replication after Pathogenic SIV Infection Michael A. Egan, William A. Charini, Marcelo J. Kuroda, Journal of Virology	2000	143

Page 1